#beLab2122

Novel ACE2 fusion protein with adapting activity against SARS-CoV-2 variants in vitro - PubMed Despite the successful development of vaccines and neutralizing antibodies to limit the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerging variants prolong the pandemic and emphasize the persistent need to develop effective antiviral treatment regimens. Recombinant anti …

Their ACE2-M fusion protein offers a promising new therapy against SARS-CoV-2, effective even against escape variants. Amazing work! #Innovation #Science2Start #biotech #COVID19 #beLab2122
👉https://pubmed.ncbi.nlm.nih.gov/36969164/